


Index Chart



(Source: [Bloomberg](#))

Indian Markets

Indices	Close	Previous	Change(%)
NIFTY 50	22512.65	23114.50	-2.60%
S&P BSE SENSEX	72696.39	74532.96	-2.46%
NIFTY MID100	52717.55	54855.50	-3.90%
NIFTY SML100	15098.70	15718.60	-3.94%

(Source: [NSE](#), [BSE](#))

Market Wrap Up

- The key equity indices ended sharply lower as escalating tensions between the US and Iran, along with a weakening rupee and rising crude oil prices, rattled investor sentiment. The Nifty closed below the 22,550 mark.
- The S&P BSE Sensex tanked 1,836.57 points or 2.46% to 72,696.39. The Nifty 50 index plunged 601.85 points or 2.60% to 22,512.65.
- The BSE 150 MidCap Index dropped 3.81% and the BSE 250 SmallCap Index slipped 3.86%.
- Among the sectoral indices, the IT index (down 0.18%), the Nifty Healthcare index (down 2.11%) and the Nifty Pharma index (down 2.16%) outperformed the Nifty 50 index.
- Meanwhile, the Nifty Consumer Durables index (down 5.17%), the Nifty Metal index (down 4.81%) and the Nifty Realty index (down 4.74%) underperformed the Nifty 50 index.

(Source: Capitaline Market Commentary)

Derivative Watch

- Nifty **March** series futures witnessed a fresh **short** position build up. Open Interest has been increased by **7121** contracts at the end of the day.
- **Long** position build up for the **March** series has been witnessed in **HCLTECH, COFORGE**.
- **Short** position build up for the **March** series has been witnessed in **RELIANCE, LT, BHARTIARTL, SBIN, ICICIBANK, HDFCBANK, INFY**.
- **Unwinding** position for the **March** series has been witnessed in **ZYDUSLIFE, BIOCON, COLPAL**.

(Source: Capitaline F&O)

Sectoral Indices

Indices	Close	Previous	Change(%)
NIFTY BANK	51437.75	53427.05	-3.72%
NIFTY AUTO	23934.75	24715.90	-3.16%
NIFTY FMCG	45837.05	47007.55	-2.49%
NIFTY IT	29147.05	29199.60	-0.18%
NIFTY METAL	10863.45	11412.75	-4.81%
NIFTY PHARMA	22053.10	22540.70	-2.16%
NIFTY REALTY	663.40	696.40	-4.74%
BSE CG	64657.74	67344.39	-3.99%
BSE CD	52061.30	54751.36	-4.91%
BSE Oil & GAS	25167.25	25977.38	-3.12%
BSE POWER	6731.63	6923.81	-2.78%

(Source: [NSE](#), [BSE](#))

Asia Pacific Markets

Indices	Close	Previous	Change (%)
NIKKEI225	51515.49	53372.53	-3.48%
HANG SENG	24382.47	25277.32	-3.54%
STRAITS TIMES	4841.30	4948.87	-2.17%
SHANGHAI	3813.28	3957.05	-3.63%
KOSPI	5405.75	5781.20	-6.49%
JAKARTA	CLOSED	CLOSED	-
TAIWAN	32722.50	33543.88	-2.45%
KLSE COMPOSITE	CLOSED	CLOSED	-
ALL ORDINARIES	8552.60	8628.30	-0.88%

(Source: [Yahoo Finance](#))

Exchange Turnover (Crores)

Market	Current	Previous
NSE Cash	130437.72	140228.16
NSE F&O	270215.95	241188.43

(Source: [NSE](#))

FII Activities (Crores)

ACTIVITIES	Cash
NET BUY	-
NET SELL	10414.23

(Source: [NSE](#))

Corporate News

- Tata Steel** and **Hindustan Zinc** have joined forces. They will use EcoZen, a low-carbon zinc, in steel production. This partnership aims to make steel manufacturing more sustainable. EcoZen uses renewable energy and has a much lower carbon footprint. This collaboration supports India's move towards greener industries. It helps reduce emissions across the supply chain.
- Adani Green Energy** has commissioned 510 megawatt of power projects in Khavda, Gujarat. This development boosts its total operational renewable generation capacity to 17,982.3 megawatt. The new plants, operationalised through stepdown subsidiaries, commenced power generation from March 22.
- Kotak Mahindra Bank** is poised to take a major leap by acquiring Deutsche Bank's retail operations in India for around Rs 4,500 crore. This deal promises to strengthen Kotak's retail lending capabilities and broaden its base of deposits. Meanwhile, Deutsche Bank's exit reflects a larger strategy to streamline its operations worldwide.
- HDFC Bank** has terminated three senior employees after an internal investigation into alleged mis-selling of AT1 bonds to NRI clients. The action follows a detailed review of transactions conducted via the bank's overseas operations. The transactions were primarily linked to its Dubai branch. The issue relates to the sale of Credit Suisse AT1 bonds. These bonds were written off after Credit Suisse went bankrupt and was taken over by another banking giant, UBS. Some NRI clients were encouraged to move FCNR deposits to overseas accounts. These funds were then used to invest in high-risk AT1 bonds. The development comes amid regulatory scrutiny and investor concerns. It also adds to pressure following the recent resignation of part-time chairman Atanu Chakraborty.
- Ashok Leyland** announced that the company has approved an investment of up to GBP 30 million (approximately Rs 375 crore) in its UK-based subsidiary, Optare Plc, to be made as equity in one or more tranches.
- DCX Systems** secured an order worth Rs 563.45 crore from a domestic customer for the manufacture and supply of maritime patrol radar systems (MPR) for

Top Gainers

SCRIP NAME	Close	Previous	Change (%)
HCLTECH	1358.60	1333.70	1.87%
POWERGRID	302.10	297.60	1.51%
INFY	1256.80	1255.90	0.07%
ONGC	265.45	265.40	0.02%

(Source: [Moneycontrol](#))

Top Losers

SCRIP NAME	Close	Previous	Change (%)
SHRIRAMFIN	877.70	938.60	-6.49%
TITAN	3853.10	4106.60	-6.17%
TRENT	3356.70	3559.60	-5.70%
JIOFIN	226.10	239.30	-5.52%
ULTRACEMCO	10362.00	10934.00	-5.23%

(Source: [Moneycontrol](#))

- **BITES** said that it has secured a comprehensive maintenance contract worth Rs 105.69 crore from Research Designs and Standards Organisation.
- **Tata Motors Passenger Vehicle** announced that it will increase the prices of its internal combustion engine (ICE) passenger vehicle portfolio, effective from 1st April 2026, to mitigate higher input costs.
- **Ceigall India** announced that its wholly owned subsidiary, Ceigall Infra projects has emerged as lowest bidder (L1) from National Highways Authority of India (NHAI) for the construction of 10.3 km highway under hybrid annuity mode (HAM) in Punjab.

airborne applications.

- **Sun Pharmaceutical Industries** has announced the launch of its semaglutide injection in India under the brand names Noveltrat and Sematrinity, across multiple strengths for the treatment of obesity and Type 2 diabetes. The company said Noveltrat is indicated for chronic weight management in adults, to be used alongside a reduced-calorie diet and increased physical activity. It is available in five dose strengths, 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL.
- **Dr Reddy's Laboratories** has announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to GLP-1 receptor agonist-based therapy for the management of Type 2 diabetes in India.
- **Zyudus Lifesciences** has announced the launch of semaglutide injection in India under the brand names Semaglyntm, Mashematm, and Altermetm, following the expiry of the drug's patent in the country.
- **Glenmark Pharmaceuticals** has announced the launch of GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), positioning it as a more affordable GLP-1 therapy aimed at expanding access to advanced diabetes treatment.
- **Alkem Laboratories** announced that it has received a Good Manufacturing Practices (GMP) compliance certificate from the Malta Medicines Authority for its manufacturing facility located in Daman, India.
- **Vedanta** announced a third interim dividend of Rs 11 per equity share.

(Source: [Business Standard](#), [Economic Times](#), [Smart investor](#))

Global News

- Italy's trade balance showed a surplus of EUR 1.1 billion in January versus a shortfall of EUR 288 million in the corresponding month last year. Exports fell 4.6% annually in January, and imports plunged by 7.4%.
- Italy's current account gap narrowed to EUR 1.8 billion in January from EUR 4.2 billion in the corresponding month last year.
- Singapore's annual inflation rate edged lower to 1.2% in February 2026, from a thirteen-month high of 1.4% in the previous month. On a monthly basis, consumer prices increased 0.6%, rebounding from a 0.5% decline in January.
- Hong Kong's consumer price inflation climbed 1.7% year-over-year in February, faster than January's rise of 1.1%.

(Source: [Market Watch](#), [RTT News](#), [Reuters](#), [Bloomberg](#))

Economic News

- Crude Oil traded at US\$ 92.05/bbl (IST 17:00).
- INR weakened to Rs. 93.98 from Rs. 93.72 against each US\$ resulting in daily change of 0.28%.
- A new bill to amend corporate laws was introduced in the Lok Sabha. The legislation seeks changes to the Limited Liability Partnership Act and the Companies Act. The bill has been sent to a Joint Parliamentary Committee for a thorough review. The Finance Minister will also present the Finance Bill, 2026.
- India's trade investigation body has recommended anti-dumping duties of \$386-\$1,071 per metric ton on viscose rayon filament yarn imports from China to counter unfair pricing
- India and the European Union are boosting cooperation following their January summit. Several initiatives are planned in the coming months. These include parliamentary visits, consultations on the Indo-Pacific region, and ministerial meetings for the Trade and Technology Council. Both sides aim to complete a Security of Information Agreement this year.
- Indian sugar mills are exporting again. A weaker rupee and higher global prices make overseas sales profitable. Around 100,000 tons have been booked in a week. Asian and African nations will benefit from lower prices. This comes as global sugar prices are near a five-month high. India's sugar exports are expected to reach 1.5 million tons this season.

(Source: [Economic Times](#), [Business Standard](#))

Forthcoming Events

Board Meetings as on 24/03/2026

TVS Motor Company Limited	Dividend
Solara Active Pharma Sciences Ltd	Alteration of form or nature or rights of securities
Ashapura Minechem Limited	ESOP
Viji Finance Limited	Fund Raising

(Source: NSE)

Corporate Actions as on 24/03/2026

Kilitch Drugs (India) Limited	Bonus 1:1
-------------------------------	-----------

(Source: NSE)

DISCLAIMER

This document has been prepared by Shriram Insight Share Brokers Ltd. and is meant for sole use by the recipient and not for circulation. This document is not to be reported or copied or made available to others. The information contained herein is from sources believed reliable. It should not be considered as an offer to sell or a solicitation to buy any security or as an official confirmation of any transaction. We do not represent that it is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The investments discussed or recommended in this report may not be suitable for all investors. Shriram Insight Share Brokers Ltd. Stock Recommendation Service is a general recommendation service and is not to be construed as an individual investor-specific Portfolio Management and Advisory Service.

The user assumes the entire risk of any use made of this information. Each recipient of this document should arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult their own advisors to determine the merits and risks of such an investment.

Shriram Insight Share Brokers Ltd. shall not be responsible for any loss or liability incurred to the user as a consequence of his or any other person on his behalf taking any investment decisions based on the information, recommendations, research reports, analysis, quotes, etc. provided on the web site.

Shriram Insight Share Brokers Ltd shall not be liable for errors, omissions or typographical errors, disruption delay, interruption, failure, deletion or defect of/in the Service provided by it.

All Users of the Service in countries other than India understand that by using the Service, they may be violating the local laws in such countries. If the User chooses to access the Service from outside India, he shall be responsible for compliance with foreign and local laws.

EQUITIES | DERIVATIVES | COMMODITIES | DP SERVICES | MUTUAL FUNDS | RESEARCH

SHRIRAM INSIGHT SHARE BROKERS LTD. CK-5, Sector-II, Salt Lake City, Kolkata - 700091 | Tel : 2359 4612, 2359 4614, 2359 4877 | Fax : (033) 2321-8429 | E-mail : helpdesk@shriraminsight.com | www.shriraminsight.com |